ExamPro - Your answer to the Boards

ExamPro Store | Member's Area | Latest ExamPro News

Today: 5/18/2008

"You targeted at least 90% of the questions!"

2007 ExamPro pass rate: 96.8%

Next seminar:

Only 0 days to go!
See details

About | FAQs | Contact | Testimonials | Newsletter

Main Menu

For a very insightful taste of ExamPro, click here.

Tell a Colleague about ExamPro

To sign up for any of our seminars go to the ExamPro Store

Our Seminars

ExamPro MCQ Tests

MCQ Test: Endometrial Neoplasia

Number of questions in this MCQ test: 6
Suggested time for this MCQ test: 7 minutes

The most important predictor of the behavior of an endometrial hyperplasia is:
Patient age
Presence of atypia
Complex vs. simple hyperplasia
Hormone (estrogen) receptor status of tissue obtained at curettage
Presence of aneuploidy
In patients with complex atypical endometrial hyperplasia by endometrial biopsy or curettage, what percentage will actually have endometrail cancer at hystectomy?
< 1%
< 5%
< 10%
< 15 %
> 25%
A 29-year-old woman is found to have an endometrial cancer. All of the following would be expected, with the EXCEPTION of:
The patient probably has chronic anovulation and may have polycystic ovarian syndrome
The tumor is well differentiated and is non-invasive or superficially invasive into the myometrium
May potentially be treated with the use of progestins
A pelvic ultrasound would be beneficial to rule out a synchronous ovarian neoplasm
Probably has a tumor with nonendometrioid histology
Which of the following is false in regard to non-endometrioid adenocarcinomas of the uterus?
Non-endometrioid adenocarcinomas constitute about 10% of endometrial cancers
Are biologically more aggressive than the traditional endometrioid adenocarcinoma
Can demonstrate clear cell and papillary serous histologies
In the absence of adnexal involvement, these tumors do not have an adverse prognosis
Are staged in the same manner as endometrioid adenocarcinomas
All of the following are true about tamoxifen and raloxifen in regards to endometrial neoplasia EXCEPT :
Tamoxifen increases the risk endometrial cancers twofold to threefold
An annual endometrial biopsy in asymptomatic patients on tamoxifen is not necessary
Tamoxifen and raloxifen are selective estrogen receptor modulators
Raloxifen increases the risk of endometrial hyperplasia and adenocarcinomas
Tamoxifen administration increases the thickness of the endometrail stripe; Routine ultrasound surveillance in asymptomatic patients on taxoxifen is not useful
Which of the following are true in regards to uterine sarcomas?
Although saecomas account for only 3% of uterine cancers, they often have a poor prognosis
Leiomyosarcomas usually arise de novo from the uterine smooth muscle, rather than from a preexisting fibroid
Rapid enlargement of a presumed fibroid uterus is a potential sign of a leiomyosarcoma
There is no offical staging system for uterine sarcomas, but it is customary to use the FIGO system for endometrial cancers
All of the above are true

Return to Quiz HomePage

To purchase any of our products go to the ExamPro Store

Please note: All manuals and disks are for the use of the original purchaser only and may not be resold or copied.

Tel 410 580-2970, Fax: 410 580-2971